Improved clinical outcomes with liver transplantation for hepatitis B- induced chronic liver failure using passive immunization

Annals of Surgery

Volumn 227, Issue 6, 1998, Pages 841-850

  Sawyer, Robert G ^a,b   McGory, Robert W ^a   Gaffey, Michael J ^a   McCullough, Christopher C ^a   Shephard, Barbara L ^a   Houlgrave, C Webster ^a   Ryan, Terry S ^a   Kuhns, Mary ^c   McNamara, Anne ^c   Caldwell, Stephen H ^a   Abdulkareem, Abdulmajeed ^a   Pruett, Timothy L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; VIRUS DNA;

ANTIBODY BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GRAFT INFECTION; HEPATITIS B; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOPROPHYLAXIS; LIVER BIOPSY; LIVER TRANSPLANTATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REINFECTION; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS TYPING;

ADULT; AGED; CHRONIC DISEASE; DNA, VIRAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNIZATION, PASSIVE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032461668     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199806000-00007     Document Type: Article

References (24)

1. Freeman RB, Sanchez H, Lewis WD, et al. Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 1991; 51:793-797.
2. Rizzetto M, Recchia S, Salizzoni M. Liver transplantation in carriers of the HBsAg. J Hepatol 1991; 13:5-7.
3. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B reinfection after orthotopic liver transplantation. J Hepatol 1992; 14:104-111.
4. Konig V, Hopf U, Neuhaus P, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58:553-559.
5. Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19:4051-4053.
6. Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13:90-96.
7. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813-815.
8. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842-1847.
9. Terrault N, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:1327-1333.
10. McGory RW, Ishitani MB, Oliviera WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:1358-1364.
11. Lowell JA, Burgess S, Shenoy S, et al. Mercury poisoning associated with hepatitis B immunoglobulin. Lancet 1996; 347:480.
12. Al-Hemsi B, McGory RW, Shephard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 1996; 10:668-675.
13. McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene coding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15:757-766.
14. Cariani E, Ravaggi A, Tanzi E, et al. Emergence of hepatitis B virus S mutant in a liver transplant recipient. J Med Virol 1995; 47:410-415.
15. Hawkins AE, Gilson RJ, Gilbert N, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996; 24:8-14.
16. Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489-493.
17. Terrault NA, Zhou S, Singleton S, et al. Mutational analysis of surface (S) and polymerase (P) genes in liver transplant recipients failing HBIg prophylaxis. Hepatology 1996; 24:181A.
18. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-713.
19. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-22.
20. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-329.
21. Waters JA, Kennedy M, Voet P, et al. Loss of the common A determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90:2543-2547.
22. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212-1215.
23. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62:1456-1462.
24. Mann SP, Painter DM, McCaughan GW. Histopathological prediction of hepatitis B recurrence in liver allografts. Pathology 1994; 26:251-256.